Robert Michiels

415 Capital Management GmbH (415 Capital) is an independent venture capital firm founded in 2018 by Frank Gabriel Groenewegen, David P. Thompson and Frederik Justin Gabriel Groenewegen. The firm is headquartered in Oberhaching, Germany.

415 Capital Management GmbH (415 Capital) is an independent venture capital firm founded in 2018 by Frank Gabriel Groenewegen, David P. Thompson and Frederik Justin Gabriel Groenewegen. The firm is headquartered in Oberhaching, Germany.

415 Capital Management GmbH (415 Capital) is an independent venture capital firm founded in 2018 by Frank Gabriel Groenewegen, David P. Thompson and Frederik Justin Gabriel Groenewegen. The firm is headquartered in Oberhaching, Germany.

415 Capital Management GmbH (415 Capital) is an independent venture capital firm founded in 2018 by Frank Gabriel Groenewegen, David P. Thompson and Frederik Justin Gabriel Groenewegen. The firm is headquartered in Oberhaching, Germany.

415 Capital Management GmbH (415 Capital) is an independent venture capital firm founded in 2018 by Frank Gabriel Groenewegen, David P. Thompson and Frederik Justin Gabriel Groenewegen. The firm is headquartered in Oberhaching, Germany.

415 Capital Management GmbH (415 Capital) is an independent venture capital firm founded in 2018 by Frank Gabriel Groenewegen, David P. Thompson and Frederik Justin Gabriel Groenewegen. The firm is headquartered in Oberhaching, Germany.

FEops NV develops novel simulation technology. It provides cardiovascular device and procedure simulation advice to medical device companies, as well as to medical specialists and physicians. The firm develops disruptive technology: a cloud-based simulation platform designed to assist clinicians in assessing the effect of device-and-host interaction, with the ultimate goal of predicting and preventing complications of transcatheter-based structural heart interventions. The company was founded by Benedict Verhegghe, Matthieu De Beule and Peter Mortier in 2009 and is headquartered in Ghent, Belgium.

FEops NV develops novel simulation technology. It provides cardiovascular device and procedure simulation advice to medical device companies, as well as to medical specialists and physicians. The firm develops disruptive technology: a cloud-based simulation platform designed to assist clinicians in assessing the effect of device-and-host interaction, with the ultimate goal of predicting and preventing complications of transcatheter-based structural heart interventions. The company was founded by Benedict Verhegghe, Matthieu De Beule and Peter Mortier in 2009 and is headquartered in Ghent, Belgium.

FEops NV develops novel simulation technology. It provides cardiovascular device and procedure simulation advice to medical device companies, as well as to medical specialists and physicians. The firm develops disruptive technology: a cloud-based simulation platform designed to assist clinicians in assessing the effect of device-and-host interaction, with the ultimate goal of predicting and preventing complications of transcatheter-based structural heart interventions. The company was founded by Benedict Verhegghe, Matthieu De Beule and Peter Mortier in 2009 and is headquartered in Ghent, Belgium.

FEops NV develops novel simulation technology. It provides cardiovascular device and procedure simulation advice to medical device companies, as well as to medical specialists and physicians. The firm develops disruptive technology: a cloud-based simulation platform designed to assist clinicians in assessing the effect of device-and-host interaction, with the ultimate goal of predicting and preventing complications of transcatheter-based structural heart interventions. The company was founded by Benedict Verhegghe, Matthieu De Beule and Peter Mortier in 2009 and is headquartered in Ghent, Belgium.

FEops NV develops novel simulation technology. It provides cardiovascular device and procedure simulation advice to medical device companies, as well as to medical specialists and physicians. The firm develops disruptive technology: a cloud-based simulation platform designed to assist clinicians in assessing the effect of device-and-host interaction, with the ultimate goal of predicting and preventing complications of transcatheter-based structural heart interventions. The company was founded by Benedict Verhegghe, Matthieu De Beule and Peter Mortier in 2009 and is headquartered in Ghent, Belgium.

Atrius Ltd. operates a healthcare center. The company is based in Ledbury, UK. The British company was founded in 2003 by William N. Starling, who has been the CEO since 2003.